secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0000950170-25-064983
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q1 net loss $45.2M; DURAVYU Phase 3 wet AMD enrollment over 90% in LUGANO, >50% in LUCIA
--------------------------------------------------------------------------------

- Total net revenue $24.5M (up from $11.7M YoY); net loss $45.2M ($0.65 per share) vs $29.3M ($0.55) prior year.
- Cash, equivalents, and marketable securities $318.2M; runway into 2027 past Phase 3 topline data expected 2H 2026.
- LUGANO trial >90% enrolled, LUCIA >50%; enrollment on track to complete 2H 2025.
- Phase 2 VERONA in DME met endpoints; subgroup showed BCVA +10.3 letters vs +3.0 for aflibercept at week 24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025064983/0000950170-25-064983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025064983/eypt-20250507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer